A detailed history of Royal Bank Of Canada transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 3,288 shares of RAPT stock, worth $2,729. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,288
Previous 3,091 6.37%
Holding current value
$2,729
Previous $9,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.76 - $3.75 $346 - $738
197 Added 6.37%
3,288 $6,000
Q2 2024

Aug 14, 2024

BUY
$2.89 - $9.38 $4,407 - $14,304
1,525 Added 97.38%
3,091 $9,000
Q1 2024

Nov 05, 2024

SELL
$6.87 - $26.45 $10,476 - $40,336
-1,525 Reduced 49.34%
1,566 $14,000
Q1 2024

May 15, 2024

SELL
$6.87 - $26.45 $52,816 - $203,347
-7,688 Reduced 83.08%
1,566 $14,000
Q4 2023

Feb 14, 2024

BUY
$11.28 - $25.46 $56,129 - $126,688
4,976 Added 116.32%
9,254 $229,000
Q3 2023

Nov 14, 2023

BUY
$16.34 - $24.66 $18,202 - $27,471
1,114 Added 35.21%
4,278 $71,000
Q2 2023

Aug 14, 2023

BUY
$16.06 - $21.61 $23,752 - $31,961
1,479 Added 87.77%
3,164 $59,000
Q1 2023

May 15, 2023

SELL
$17.19 - $30.8 $22,501 - $40,317
-1,309 Reduced 43.72%
1,685 $30,000
Q4 2022

Feb 14, 2023

BUY
$16.28 - $24.6 $43,581 - $65,854
2,677 Added 844.48%
2,994 $59,000
Q3 2022

Nov 14, 2022

BUY
$17.96 - $30.46 $3,053 - $5,178
170 Added 115.65%
317 $8,000
Q2 2022

Aug 15, 2022

SELL
$10.26 - $23.59 $11,922 - $27,411
-1,162 Reduced 88.77%
147 $3,000
Q1 2022

May 16, 2022

SELL
$17.02 - $40.22 $53,936 - $127,457
-3,169 Reduced 70.77%
1,309 $29,000
Q4 2021

Feb 14, 2022

BUY
$29.5 - $39.5 $79,473 - $106,413
2,694 Added 151.01%
4,478 $164,000
Q3 2021

Nov 15, 2021

BUY
$29.86 - $39.47 $16,542 - $21,866
554 Added 45.04%
1,784 $55,000
Q2 2021

Aug 16, 2021

BUY
$17.99 - $40.02 $22,127 - $49,224
1,230 New
1,230 $39,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $24.6M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.